Technical Analysis for NVCR - NovoCure Limited

Grade Last Price % Change Price Change
grade A 111.31 2.12% 2.31
NVCR closed up 2.12 percent on Wednesday, September 30, 2020, on 88 percent of normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical NVCR trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
New 52 Week High Strength 0.00%
Multiple of Ten Bullish Other 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Shooting Star Candlestick Bearish 2.12%
NR7 Range Contraction 2.12%
NR7-2 Range Contraction 2.12%
Older End-of-Day Gignals for NVCR ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 13 hours ago
Rose Above Previous Day's High about 17 hours ago
New 52 Week High about 17 hours ago
Up 3% about 17 hours ago
Up 2% about 17 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


NovoCure Limited develops and commercializes treatment for solid tumor cancers therapy called the tumor treating fields (TTFields). The company markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. NovoCure Limited also conducts clinical trials for the use of TTFields in brain metastases, advanced non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma. The company markets its products in the United States, as well as in European Union member states, Switzerland, and Japan. NovoCure Limited was founded in 2000 and is based in Saint Helier, Channel Islands.
Medicine Cancer Clinical Medicine Oncology Tumor Non Small Cell Lung Cancer Ovarian Cancer Pancreatic Cancer Glioblastoma Aging Associated Diseases European Union Brain Tumor Solid Tumor Cancers Mesothelioma

Is NVCR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 113.21
52 Week Low 53.4
Average Volume 994,166
200-Day Moving Average 75.50
50-Day Moving Average 85.24
20-Day Moving Average 98.76
10-Day Moving Average 107.41
Average True Range 4.24
ADX 39.66
+DI 39.78
-DI 16.77
Chandelier Exit (Long, 3 ATRs ) 100.48
Chandelier Exit (Short, 3 ATRs ) 88.76
Upper Bollinger Band 120.66
Lower Bollinger Band 76.85
Percent B (%b) 0.79
BandWidth 44.37
MACD Line 7.65
MACD Signal Line 7.40
MACD Histogram 0.2531
Fundamentals Value
Market Cap 9.9 Billion
Num Shares 88.9 Million
EPS -1.09
Price-to-Earnings (P/E) Ratio -102.12
Price-to-Sales 13.08
Price-to-Book 13.88
PEG Ratio -0.41
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 117.51
Resistance 3 (R3) 117.45 115.33 116.47
Resistance 2 (R2) 115.33 113.75 115.36 116.13
Resistance 1 (R1) 113.32 112.78 114.33 113.38 115.78
Pivot Point 111.20 111.20 111.70 111.23 111.20
Support 1 (S1) 109.19 109.62 110.20 109.25 106.84
Support 2 (S2) 107.07 108.65 107.10 106.49
Support 3 (S3) 105.06 107.07 106.15
Support 4 (S4) 105.12